From Drug Design to Phase 3 Success in RAS-Driven Disease
Andrew H. Ko, MD
Eileen O'Reilly, MD
Shubham Pant, MD, MBBS
Rachna Shroff, MD, MS, FASCO
Rahul Gosain, MD, MBA
Key Points
- Daraxonrasib acts via the cyclophilin A–mediated “molecular glue” mechanism.
- RASolute 302 was a global phase 3 randomized trial that enrolled approximately 500 patients.
- Investigators compared oral targeted therapy versus investigator’s choice chemotherapy.
- The trial included survival, response, and patient-reported outcome end points.
The panel discussion, cohosted by Rahul Gosain, MD, MBA, and Rohit Gosain, MD, shifted to the biological rationale and trial design underpinning RASolute 302. Participants included Andrew H. Ko, MD, of the University of California, San Francisco; Eileen O’Reilly, MD, of Memorial Sloan Kettering Cancer Center; Shubham Pant, MD, MBBS, of The University of Texas MD Anderson Cancer Center; and Rachna Shroff, MD, MS, FASCO, of the University of Arizona.
Investigators highlighted both the complexity of RAS signaling and the novelty of successfully targeting a pathway long considered undruggable. KRAS alterations, particularly at codon 12, dominate pancreatic cancer biology and drive MAP kinase pathway activation that promotes tumor proliferation and survival.
Mechanistically, daraxonrasib was described as a molecular glue that binds cyclophilin A and stabilizes interaction with active RAS protein, leading to steric disruption of oncogenic signaling. This ultimately results in cancer cell death while also engaging immune-mediated antitumor effects, representing a dual-mechanism approach within a single oral agent.
The phase 3 RASolute 302 study enrolled approximately 500 patients with metastatic pancreatic adenocarcinoma after 1 prior line of therapy. Participants were randomized to daily oral daraxonrasib versus investigator’s choice chemotherapy. The control arm included commonly used cytotoxic regimens selected according to investigator discretion. The trial incorporated dual primary end points of overall survival and progression-free survival in KRAS G12-mutant disease, alongside broader intention-to-treat analyses.
Beyond survival outcomes, the study also incorporated response rates and patient-reported outcomes, allowing for assessment of quality of life alongside efficacy. This design reinforced the intent to evaluate not only tumor control but also functional and symptomatic benefit in a population with significant disease burden.